Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ ...

Organovo Holdings, Inc. (Nasdaq:ONVO) (“Organovo” or the “Company”), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease (IBD) today ...

The deal with Lilly is a crucial boost for Organovo, which ended last year with just $1.2 million in cash and nearly $350 million in debt. Organovo FXR is a clinical drug program focused on farnesoid ...

which includes Organovo's FXR program and its lead asset, FXR314, aimed at treating inflammatory bowel disease (IBD). Keith Murphy, Executive Chairman of Organovo, expressed excitement about the ...

Organovo shares are trading higher by 246% Tuesday morning. The company announced that Eli Lilly is set to acquire its FXR ...

Among significant research news last week, US CNS specialist Axsome Therapeutics released new Phase III data on its recently ...

(“Lilly”) will acquire Organovo’s FXR program, including its lead asset, FXR314. “This is a significant milestone for our efforts to advance medicines for IBD using insights from our ...

Holdings announced that Eli Lilly (LLY) and Company will acquire Organovo’s FXR program, including its lead asset, FXR314. Under ...

Lilly is acquiring all commercial and intellectual property rights to Organovo’s FXR program for worldwide development. About OrganovoOrganovo is a clinical stage biotechnology company that is ...